德力克斯和雷格内伦合作开发用于固体瘤的放射性药物治疗. Telix and Regeneron partner to develop radiopharmaceutical therapies for solid tumors.

德力克斯制药公司和雷格内伦制药已经合作开发并商业化下一代放射性药物治疗固体瘤. Telix Pharmaceuticals and Regeneron Pharmaceuticals have partnered to co-develop and commercialize next-generation radiopharmaceutical therapies for solid tumors. 协议包括4000万美元的预付款和可能达到21亿美元的里程碑性支付. The agreement includes an upfront payment of $40 million and potential milestone payments of up to $2.1 billion. 两家公司将平等分担成本和利,重点关注精密的癌症研究以及利用Regeneron抗体发现技术. The companies will share costs and profits equally, focusing on precision oncology and leveraging Regeneron's antibody discovery technology.